A simple blood test to choose the best treatment for each patient with depression.broad
RxMine · Horizon Europe grant · 2022-06-01–2025-05-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to 170 billion to the EU. Despite numerous available drugs, 75% of patients do not receive adequate treatment, 63% try multiple medications, and a third do not respond after two rounds of treatment. This trial-and-error approach is destructive to patients, time-consuming for physicians and expensive to health care systems. RxMine revolutionizes this process by combining innovative stem cell technology, genetics, neurobiology, high-throughput screening and machine learning to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model. RxMine identifies the optimal antidepressant for each patient and potentially reduces hospitalizations by 89%, emergency-room visits by 71% and depression related healthcare costs by 40% with savings up to 6,000 per patient per year.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| GENETIKAPLUS LTD | IL | coordinator | €2,499,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.